|
MED19 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6242562850266E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-16 |
| Normal-vs-Stage2 |
3.83890000010823E-07 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
2.472400E-01 |
| Stage1-vs-Stage3 |
7.782100E-02 |
| Stage1-vs-Stage4 |
6.29730000000217E-05 |
| Stage2-vs-Stage3 |
5.174200E-02 |
| Stage2-vs-Stage4 |
8.763100E-04 |
| Stage3-vs-Stage4 |
2.958000E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.06219999462809E-09 |
| Normal-vs-Asian |
3.4313000218944E-09 |
| Caucasian-vs-AfricanAmerican |
2.970800E-01 |
| Caucasian-vs-Asian |
3.360400E-01 |
| AfricanAmerican-vs-Asian |
1.242750E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
2.702000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.26041407813682E-13 |
| Normal-vs-Age(41-60Yrs) |
1.12132525487141E-14 |
| Normal-vs-Age(61-80Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(81-100Yrs) |
4.89899999456256E-08 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.610400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.762200E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.081400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.196400E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.768300E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.694000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.174110E-04 |
| Classical-VS-Follicular |
5.271400E-01 |
| Classical-VS-Other |
4.922000E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
1.002730E-03 |
| Tall-VS-Other |
2.277800E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
5.696600E-01 |
| Follicular-VS-Normal |
3.2084002121735E-11 |
| Other-VS-Normal |
2.076400E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.88178419700125E-16 |
| Normal-vs-N1 |
1.62647673107585E-12 |
| N0-vs-N1 |
9.476800E-03 |
|
|
